Compare DHIL & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DHIL | CYRX |
|---|---|---|
| Founded | 1990 | 1999 |
| Country | United States | United States |
| Employees | N/A | 1100 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.8M | 419.3M |
| IPO Year | 1996 | 2008 |
| Metric | DHIL | CYRX |
|---|---|---|
| Price | $171.56 | $9.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.94 |
| AVG Volume (30 Days) | 16.8K | ★ 392.7K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.48% | N/A |
| EPS Growth | 14.37 | ★ 156.22 |
| EPS | ★ 17.91 | 1.40 |
| Revenue | $145,201,729.00 | ★ $176,177,000.00 |
| Revenue This Year | N/A | $11.06 |
| Revenue Next Year | N/A | $8.45 |
| P/E Ratio | $9.64 | ★ $6.26 |
| Revenue Growth | ★ 6.69 | N/A |
| 52 Week Low | $114.11 | $4.63 |
| 52 Week High | $173.70 | $11.45 |
| Indicator | DHIL | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.17 | 63.57 |
| Support Level | $171.96 | $9.18 |
| Resistance Level | $173.56 | $9.32 |
| Average True Range (ATR) | 0.66 | 0.43 |
| MACD | -0.13 | 0.14 |
| Stochastic Oscillator | 35.96 | 92.51 |
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.